Literature DB >> 16643452

Pulmonary hypertension in thalassaemia major patients with normal left ventricular systolic function.

R W Hagar1, C R Morris, E P Vichinsky.   

Abstract

Pulmonary hypertension is common in adults with thalassaemia and other haemolytic anaemias. It was hypothesised that regular transfusions in thalassaemia major should both decrease the chronic haemolytic rate and be protective from pulmonary hypertension (PHT). To reduce the contribution of existing cardiac disease to PHT, the subjects were limited to patients with normal left ventricular shortening fractions. Associations with multiple laboratory markers of haemolysis, serum ferritin levels, chest X-rays findings and splenectomy status were also considered. We found no biochemical, transfusional, or clinical (except gender) differences in transfused thalassaemia patients with or without pulmonary hyper tension.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16643452     DOI: 10.1111/j.1365-2141.2006.06053.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  12 in total

1.  Pulmonary arterial hypertension in a patient with β-thalassemia intermedia and reversal with infusion epoprostenol then transition to oral calcium channel blocker therapy: review of literature.

Authors:  Kamonpun Ussavarungsi; Charles D Burger
Journal:  Pulm Circ       Date:  2014-09       Impact factor: 3.017

Review 2.  Pulmonary complications of sickle cell disease.

Authors:  Andrew C Miller; Mark T Gladwin
Journal:  Am J Respir Crit Care Med       Date:  2012-03-23       Impact factor: 21.405

3.  Risk factors and mortality associated with an elevated tricuspid regurgitant jet velocity measured by Doppler-echocardiography in thalassemia: a Thalassemia Clinical Research Network report.

Authors:  Claudia R Morris; Hae-Young Kim; Felicia Trachtenberg; John Wood; Charles T Quinn; Nancy Sweeters; Janet L Kwiatkowski; Alexis A Thompson; Patricia J Giardina; Jeanne Boudreaux; Nancy F Olivieri; John B Porter; Ellis J Neufeld; Elliott P Vichinsky
Journal:  Blood       Date:  2011-07-19       Impact factor: 22.113

4.  Pulmonary hypertension in well-transfused thalassemia major patients.

Authors:  Antonella Meloni; Jon Detterich; Alessia Pepe; Paul Harmatz; Tom D Coates; John C Wood
Journal:  Blood Cells Mol Dis       Date:  2014-11-24       Impact factor: 3.039

5.  Sildenafil therapy in thalassemia patients with Doppler-defined risk of pulmonary hypertension.

Authors:  Claudia R Morris; Hae-Young Kim; John Wood; John B Porter; Elizabeth S Klings; Felicia L Trachtenberg; Nancy Sweeters; Nancy F Olivieri; Janet L Kwiatkowski; Lisa Virzi; Sylvia T Singer; Ali Taher; Ellis J Neufeld; Alexis A Thompson; Vandana Sachdev; Sandra Larkin; Jung H Suh; Frans A Kuypers; Elliott P Vichinsky
Journal:  Haematologica       Date:  2013-04-12       Impact factor: 9.941

6.  Vascular dysfunction in a murine model of severe hemolysis.

Authors:  Anne C Frei; YiHe Guo; Deron W Jones; Kirkwood A Pritchard; Karen A Fagan; Neil Hogg; Nancy J Wandersee
Journal:  Blood       Date:  2008-05-13       Impact factor: 22.113

Review 7.  Pulmonary hypertension associated with chronic hemolytic anemia and other blood disorders.

Authors:  Roberto F Machado; Harrison W Farber
Journal:  Clin Chest Med       Date:  2013-10-17       Impact factor: 2.878

8.  Prevalence and risk factors for pulmonary artery systolic hypertension among sickle cell disease patients in Nigeria.

Authors:  Zakari Y Aliyu; Victor Gordeuk; Vandana Sachdev; Aliyu Babadoko; Aisha I Mamman; Peter Akpanpe; Ester Attah; Yusuf Suleiman; Nurudeen Aliyu; Jamilu Yusuf; Laurel Mendelsohn; Gregory J Kato; Mark T Gladwin
Journal:  Am J Hematol       Date:  2008-06       Impact factor: 10.047

Review 9.  Pulmonary hypertension associated with thalassemia syndromes.

Authors:  Dustin R Fraidenburg; Roberto F Machado
Journal:  Ann N Y Acad Sci       Date:  2016-03-23       Impact factor: 5.691

Review 10.  Nitric oxide and arginine dysregulation: a novel pathway to pulmonary hypertension in hemolytic disorders.

Authors:  Claudia R Morris; Mark T Gladwin; Gregory J Kato
Journal:  Curr Mol Med       Date:  2008-11       Impact factor: 2.222

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.